DBV Technologies - ADR opened lower at $11.75, compared with its previous close of $11.88. In the last trading session, the stock traded between $11.25 and $11.93. It showed a downward intraday trend.
An investment of $100 made 5 years ago in DBV Technologies - ADR is now worth
$ 35.83
Resulting in a loss of
$ 64.17 (64.17%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.45 (-3.80%)
Day High
$11.93
Day Low
$11.25
Day Open
$11.75
Prev Close
$11.88
Volume
3,04,738
1W Return
15.19%
1M Return
19.40%
3M Return
-18.76%
6M Return
-43.87%
1Y Return
-14.33%
Market Cap ($ Mn)
719
PE Ratio
-
PB Ratio
4.99
PEG Ratio
-
ROE
-217.31%
ROCE
-195.86%
EPS (TTM)
$-0.21
1 Week
15.19%
1 Month
19.40%
3 Months
-18.76%
6 Months
-43.87%
9 Months
-49.43%
DBV Technologies files FDA BLA for VIASKIN Peanut Patch in kids
DBV Technologies submitted a BLA to the US FDA for VIASKIN Peanut Patch in children aged 4-7. The application requests Priority Review from the regulatory agency. Submission is supported by data from the VITESSE Phase 3 trial involving 654 participants. The trial is described as the largest immunotherapy study to date for this population.
1mo agoDBV Technologies to present at three September investor conferences
DBV Technologies will attend three investor conferences in New York in September 2026. The schedule includes fireside chats at Cantor and H.C. Wainwright events. Citi conference participation involves one-on-one meetings on September 10. Live webcasts of chats will be available on the company website for 90 days.
2mo agoDBV Technologies reports 314.4 million shares as of August 31, 2026
Total shares outstanding: 314,388,807. Gross voting rights: 314,388,807. Net voting rights: 314,222,095. Filing date: August 31, 2026. Compliance with AMF Article 223-16.
2mo agoDBV Technologies sells $50 million of ADSs via ATM program
DBV Technologies raises $50 million via an ATM offering of 3.66 million ADSs sold to RA Capital at $13.67 per share. The issuance, effective August 3, 2026, dilutes existing shareholders by 5.82% and complies with French commercial code exemptions from prospectus publication.
3mo agoDBV Technologies files ATM prospectus for up to $150 million
DBV Technologies filed a shelf registration statement to refresh its at-the-market offering program for up to $150 million. Proceeds will support manufacturing expansion, BLAs, and product development. Citizens JMP Securities is the sales agent.
3mo agoDBV Technologies narrows Q2 loss, funds operations into Q3 2027
DBV Technologies reported financial results for the second quarter and half-year ended June 30, 2026, recording a net loss of $50.4 million for the quarter. The company improved its net loss per share to $(0.12) from $(0.31) in the prior year, while holding $174.9 million in cash to fund operations into the third quarter of 2027. Operational highlights include progress toward the BLA submission for the VIASKIN Peanut Patch in the third quarter of 2026 and the closure of recruitment for the COMFORT Toddlers study.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in DBV Technologies - ADR is now worth
$ 35.83
Resulting in a loss of
$ 64.17 (64.17%)
Note: Past profits do not guarantee future returns.
